Financial Statements Company Balance Sheet at 31 December AstraZeneca PLC 2015 2014 Notes $m $m Fixed assets Fixed asset investments 1 30,047 27,426 Current assets Debtors other 15 15 Debtors amounts owed by Group undertakings 7,283 7,303 7,298 7,318 Creditors: Amounts falling due within one year Non-trade creditors 2 814 1,467 Interest-bearing loans and borrowings 3 912 814 2,379 Net current assets 6,484 4,939 Total assets less current liabilities 36,531 32,365 Creditors: Amounts falling due after more than one year Amounts owed to Group undertakings 3 283 283 Interest-bearing loans and borrowings 3 13,705 7,889 13,988 8,172 Net assets 22,543 24,193 Capital and reserves Called-up share capital 4 316 316 Share premium account 4,304 4,261 Capital redemption reserve 153 153 Other reserves 2,623 2,754 Profit and loss account 15,147 16,709 Shareholders funds 22,543 24,193 $m means millions of US dollars.
The Company Financial Statements from page 197 to 201 were approved by the Board on 4 February 2016 and were signed on its behalfby Pascal Soriot Marc Dunoyer Director Director Companys registered number 2723534 AstraZeneca Annual Report and Form 20-F Information 2015 197 Financial Statements Statement of Changes in Equity for the year ended 31 December Share Capital Share premium redemption Other Profit and Total capital account reserve reserves loss account equity $m $m $m $m $m $m At 1 January 2014 315 3,983 153 2,847 17,656 24,954 Total comprehensive income for the period Profit for the period 2,584 2,584 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 2,585 2,585 Transactions with owners, recorded directly in equity Dividends 3,532 3,532 Equity-settled share-based payment transactions 93 93 Issue of Ordinary Shares 1 278 279 Total contributions by and distributions to owners 1 278 93 3,532 3,346 At 31 December 2014 316 4,261 153 2,754 16,709 24,193 Total comprehensive income for the period Profit for the period 1,974 1,974 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 1,975 1,975 Transactions with owners, recorded directly in equity Dividends 3,537 3,537 Equity-settled share-based payment transactions 131 131 Issue of Ordinary Shares 43 43 Total contributions by and distributions to owners 43 131 3,537 3,625 At 31 December 2015 316 4,304 153 2,623 15,147 22,543 At 31 December 2015, $15,147m 31 December 2014: $16,709m of the profit and loss account reserve was available for distribution.
Included in other reserves is a special reserve of $157m, arising on the redenomination of share capital in 1999.
Included within other reserves at 31 December 2015 is $782m 31 December 2014: $913m in respect of cumulative share-based payment awards.
These amounts are not available for distribution.
198 AstraZeneca Annual Report and Form 20-F Information 2015
